SOPHiA GENETICS and MSK to Establish Precision Medicine Hub
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 04 2026
0mins
Source: PRnewswire
- MOU Signed: SOPHiA GENETICS has signed a Memorandum of Understanding with Memorial Sloan Kettering Cancer Center to establish a joint venture that combines MSK's clinical diagnostic innovations with SOPHiA's AI platform to advance precision oncology.
- Data Analysis Strength: Since 2014, SOPHiA DDM™ has analyzed over 2.5 million cases, while MSK's NGS program has sequenced more than 150,000 tumor samples, providing a robust foundation for the precision medicine hub.
- Accelerated Clinical Translation: The new hub will serve as an incubation studio for discoveries, enabling faster translation of innovations into clinical applications, potentially expanding MSK's oncology intelligence services to patients worldwide more rapidly than traditional models.
- Future Implications: This collaboration not only highlights SOPHiA GENETICS's ambitions in precision medicine but also underscores the critical role of AI in clinical decision-making, which could transform the future landscape of cancer care.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SOPH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SOPH
Wall Street analysts forecast SOPH stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.240
Low
7.00
Averages
7.00
High
7.00
Current: 5.240
Low
7.00
Averages
7.00
High
7.00
About SOPH
SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SOPHiA GENETICS Closes $57.5 Million Public Offering Amid Strong Demand
- Fundraising Amount: SOPHiA GENETICS successfully closed a public offering raising $57.5 million, reflecting strong investor demand as the offering was oversubscribed, leading underwriters to fully exercise their option for an additional 1,578,900 shares.
- Share Issuance Details: The company sold 12,104,900 ordinary shares at a public price of $4.75 per share, which included the additional shares from the underwriters' exercised option, thereby strengthening its capital base.
- Underwriter Lineup: TD Cowen acted as the lead underwriter for the offering, with Guggenheim Securities as the book-running manager, and BTIG and Craig-Hallum serving as lead managers, indicating strong market confidence in the company.
- Compliance Statement: The offering complies with the registration requirements of the Securities Act of 1933 and will not be publicly sold in Switzerland, ensuring regulatory compliance and investor protection.
See More
SOPHiA GENETICS Closes $57.5 Million Public Offering
- Significant Fundraising: SOPHiA GENETICS successfully closed a public offering raising $57.5 million, exceeding expectations and demonstrating strong investor demand, which is expected to bolster the company's capital base for future R&D and market expansion.
- Share Issuance Details: A total of 12,104,900 ordinary shares were sold at a public price of $4.75 per share, including 1,578,900 shares purchased through the underwriters' full exercise of their option, enhancing the company's liquidity and market recognition.
- Underwriter Performance: TD Cowen acted as the lead underwriter, with Guggenheim Securities as the book-running manager and BTIG and Craig-Hallum as lead managers, ensuring the successful execution of the fundraising, reflecting market confidence in the company's prospects.
- Compliance and Transparency: The company filed a registration statement with the SEC, which was declared effective on August 15, 2025, ensuring compliance with securities laws and enhancing investor trust.
See More
SOPHiA GENETICS Prices Public Offering at $4.75
- Public Offering Pricing: SOPHiA GENETICS has announced the pricing of 6,508,650 ordinary shares at $4.75 each, with gross proceeds estimated at $50 million, demonstrating the company's ability to raise capital in the market.
- Underwriter Selection: The lead book-running manager for this offering is TD Cowen, indicating the company's focus on professionalism and market influence in its choice of underwriters, aimed at boosting investor confidence.
- Additional Purchase Option: The company is also granting underwriters a 30-day option to purchase up to 10,526,000 ordinary shares at the same price, a strategy that could further enhance market liquidity and investor interest.
- Market Reaction: Following the announcement, SOPH's stock price fell by 1.60% to $4.93, reflecting a cautious market sentiment regarding the offering, which may impact future investor attitudes.
See More
SOPHiA GENETICS Prices Public Offering at $4.75
- Offering Size: SOPHiA GENETICS has priced a public offering of 10.53 million ordinary shares at $4.75 per share, raising approximately $50 million in gross proceeds, which demonstrates the company's ability to access capital markets effectively.
- Underwriter Option: The underwriters have a 30-day option to purchase up to an additional 1.58 million shares, which enhances market liquidity and investor confidence in the stock's future performance.
- Trading Performance: The stock traded about 5% lower in after-market trading on Wednesday, indicating a cautious market reaction to the offering, which may affect short-term investor sentiment.
- Closing Timeline: The offering is expected to close on June 18, 2026, marking a significant step in the company's strategic development and capital market engagement.
See More
SOPHiA GENETICS Prices Public Offering at $4.75 per Share
- Offering Size: SOPHiA GENETICS announced a public offering of 10,526,000 ordinary shares priced at $4.75 each, with gross proceeds expected to be approximately $50 million, indicating strong demand in the capital markets.
- Underwriting Arrangement: The offering is led by TD Cowen as the lead book-running manager, with Guggenheim Securities as the book-running manager and BTIG and Craig-Hallum as lead managers, ensuring professionalism and market credibility for the offering.
- Additional Share Option: The company has granted underwriters a 30-day option to purchase up to 1,578,900 additional ordinary shares, a strategy that could further enhance liquidity and support future growth initiatives.
- Compliance and Transparency: A registration statement has been filed with the SEC, and the company plans to provide a final prospectus after the offering closes, ensuring investors receive comprehensive disclosures and enhancing market trust.
See More
SOPHiA GENETICS Prices Public Offering at $4.75
- Offering Size: SOPHiA GENETICS has announced the pricing of 10,526,000 ordinary shares at $4.75 each, expecting gross proceeds of approximately $50 million, indicating strong demand in the capital markets.
- Underwriter Arrangement: TD Cowen is acting as the lead underwriter for the offering, with Guggenheim Securities as the book-running manager and BTIG and Craig-Hallum as lead managers, ensuring professional management and market coverage for the offering.
- Additional Share Option: The company has granted underwriters a 30-day option to purchase up to 1,578,900 additional ordinary shares at the same price, providing flexibility for further financing opportunities.
- Compliance and Registration: The registration statement for this offering was declared effective by the SEC on August 15, 2025, ensuring compliance and laying the groundwork for future capital operations.
See More
SOPHiA GENETICS Closes $57.5 Million Public Offering Amid Strong Demand
- Fundraising Amount: SOPHiA GENETICS successfully closed a public offering raising $57.5 million, reflecting strong investor demand as the offering was oversubscribed, leading underwriters to fully exercise their option for an additional 1,578,900 shares.
- Share Issuance Details: The company sold 12,104,900 ordinary shares at a public price of $4.75 per share, which included the additional shares from the underwriters' exercised option, thereby strengthening its capital base.
- Underwriter Lineup: TD Cowen acted as the lead underwriter for the offering, with Guggenheim Securities as the book-running manager, and BTIG and Craig-Hallum serving as lead managers, indicating strong market confidence in the company.
- Compliance Statement: The offering complies with the registration requirements of the Securities Act of 1933 and will not be publicly sold in Switzerland, ensuring regulatory compliance and investor protection.
See More
SOPHiA GENETICS Closes $57.5 Million Public Offering
- Significant Fundraising: SOPHiA GENETICS successfully closed a public offering raising $57.5 million, exceeding expectations and demonstrating strong investor demand, which is expected to bolster the company's capital base for future R&D and market expansion.
- Share Issuance Details: A total of 12,104,900 ordinary shares were sold at a public price of $4.75 per share, including 1,578,900 shares purchased through the underwriters' full exercise of their option, enhancing the company's liquidity and market recognition.
- Underwriter Performance: TD Cowen acted as the lead underwriter, with Guggenheim Securities as the book-running manager and BTIG and Craig-Hallum as lead managers, ensuring the successful execution of the fundraising, reflecting market confidence in the company's prospects.
- Compliance and Transparency: The company filed a registration statement with the SEC, which was declared effective on August 15, 2025, ensuring compliance with securities laws and enhancing investor trust.
See More
SOPHiA GENETICS Prices Public Offering at $4.75
- Public Offering Pricing: SOPHiA GENETICS has announced the pricing of 6,508,650 ordinary shares at $4.75 each, with gross proceeds estimated at $50 million, demonstrating the company's ability to raise capital in the market.
- Underwriter Selection: The lead book-running manager for this offering is TD Cowen, indicating the company's focus on professionalism and market influence in its choice of underwriters, aimed at boosting investor confidence.
- Additional Purchase Option: The company is also granting underwriters a 30-day option to purchase up to 10,526,000 ordinary shares at the same price, a strategy that could further enhance market liquidity and investor interest.
- Market Reaction: Following the announcement, SOPH's stock price fell by 1.60% to $4.93, reflecting a cautious market sentiment regarding the offering, which may impact future investor attitudes.
See More
SOPHiA GENETICS Prices Public Offering at $4.75
- Offering Size: SOPHiA GENETICS has priced a public offering of 10.53 million ordinary shares at $4.75 per share, raising approximately $50 million in gross proceeds, which demonstrates the company's ability to access capital markets effectively.
- Underwriter Option: The underwriters have a 30-day option to purchase up to an additional 1.58 million shares, which enhances market liquidity and investor confidence in the stock's future performance.
- Trading Performance: The stock traded about 5% lower in after-market trading on Wednesday, indicating a cautious market reaction to the offering, which may affect short-term investor sentiment.
- Closing Timeline: The offering is expected to close on June 18, 2026, marking a significant step in the company's strategic development and capital market engagement.
See More
SOPHiA GENETICS Prices Public Offering at $4.75 per Share
- Offering Size: SOPHiA GENETICS announced a public offering of 10,526,000 ordinary shares priced at $4.75 each, with gross proceeds expected to be approximately $50 million, indicating strong demand in the capital markets.
- Underwriting Arrangement: The offering is led by TD Cowen as the lead book-running manager, with Guggenheim Securities as the book-running manager and BTIG and Craig-Hallum as lead managers, ensuring professionalism and market credibility for the offering.
- Additional Share Option: The company has granted underwriters a 30-day option to purchase up to 1,578,900 additional ordinary shares, a strategy that could further enhance liquidity and support future growth initiatives.
- Compliance and Transparency: A registration statement has been filed with the SEC, and the company plans to provide a final prospectus after the offering closes, ensuring investors receive comprehensive disclosures and enhancing market trust.
See More
SOPHiA GENETICS Prices Public Offering at $4.75
- Offering Size: SOPHiA GENETICS has announced the pricing of 10,526,000 ordinary shares at $4.75 each, expecting gross proceeds of approximately $50 million, indicating strong demand in the capital markets.
- Underwriter Arrangement: TD Cowen is acting as the lead underwriter for the offering, with Guggenheim Securities as the book-running manager and BTIG and Craig-Hallum as lead managers, ensuring professional management and market coverage for the offering.
- Additional Share Option: The company has granted underwriters a 30-day option to purchase up to 1,578,900 additional ordinary shares at the same price, providing flexibility for further financing opportunities.
- Compliance and Registration: The registration statement for this offering was declared effective by the SEC on August 15, 2025, ensuring compliance and laying the groundwork for future capital operations.
See More
